Description
The mission of the Division of Oncology Immunotherapy is to develop and apply new immunotherapy strategies for the treatment of solid and hematologic cancers, closely linking clinical activity and scientific research.
Today, immunotherapy plays an increasingly important role in the treatment of various types of cancer. It is also emerging as a possible innovative option for patients who do not respond or are resistant to conventional therapies.
The Division works to promote research and rapidly transfer its results into clinical practice, with the goal of improving therapeutic outcomes and offering new treatment options.
The facility operates in close collaboration with the Department of Medical Oncology and the Transplantation and Cell Therapy Center, integrating clinical and research activities.
The main clinical objectives are:
- To offer treatment, monitoring and counseling programs for patients treated with immunotherapy;
- Participate and collaborate in the implementation of clinical trials dedicated to new immunotherapies;
- Collect and analyze data to evaluate the effectiveness and safety of treatments.
Research objectives include:
- investigate new cell therapies, such as TIL lymphocytes and CAR-killers, for cancers that do not respond to conventional treatments;
- Design and implement translational research studies to analyze the functioning of the immune system in patients undergoing immunotherapy or other therapies.
How to book
Find out all the ways you can access services through the National Health Service, privately and behind health funds and insurance coverage.
